/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

L

Lynne D. Berry

Berry & Associates (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

82

Papers

5.8K

Citations

24

h-index

33

i10-index

Lynne D. Berry is an academic researcher from Berry & Associates (United States). The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & RNA modifications and cancer. The author has an h-index of 24, co-authored 70 publications.

ORCID: 0000-0001-7700-2918

Research Topics

Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics RNA modifications and cancer Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Papers by this author

works

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium

2014 · Cancer · 122 citations

https://doi.org/10.1002/cncr.29042

Liza C. Villaruz Mark A. Socinski Shira Abberbock Lynne D. Berry

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

2015 · Cancer · 113 citations

https://doi.org/10.1002/cncr.29812

Conor Steuer Madhusmita Behera Lynne D. Berry Sungjin Kim

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

2023 · JTO Clinical and Research Reports · 5 citations

https://doi.org/10.1016/j.jtocrr.2023.100619

Kathryn E. Beckermann Christine M. Bestvina Badi El Osta Rachel E. Sanborn

1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study

2024 · Annals of Oncology · 0 citations

https://doi.org/10.1016/j.annonc.2024.08.1289

M. Provencio Pulla Lynne D. Berry Melanie Quintana Thomas W. LeBlanc

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

2024 · JTO Clinical and Research Reports · 0 citations

https://doi.org/10.1016/j.jtocrr.2024.100757

Nathaniel J. Myall Jennifer G. Whisenant Joel W. Neal Wade T. Iams

Research topics

topics

Lung Cancer Treatments and Mutations

Cancer Genomics and Diagnostics

RNA modifications and cancer

Lung Cancer Research Studies

Lung Cancer Diagnosis and Treatment

Chat about Author

Papers

Chat

Click to start Chat